drugset / Trial / NCT02771743

Response-based Treatment of High-risk Neuroblastoma

NCT02771743

Phase 2 Unknown 54 enrolled Samsung Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.

Timeline

Start
2015-04
Primary completion
2020-03
Completion
2023-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject Cisplatin Other / unclassified
Subject Cyclophosphamide Other / unclassified
Subject Doxorubicin Other / unclassified
Subject Etoposide Small molecule
Subject Ifosfamide Small molecule
Subject Isotretinoin Other / unclassified
Subject aldesleukin Protein / enzyme biologic

Indications